31
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cardiac Complications during Pregnancy Related to Parity in Women with Congenital Heart Disease

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective: To describe the frequency of cardiac complications during pregnancy related to parity in women with congenital heart defects. Methods: A retrospective tertiary single-center study at the Adult Congenital Heart Disease Centre that followed 307 women with congenital heart disease during the years 1997–2015 in Gothenburg, Sweden. Ma­ternal cardiac complications were noted for each pregnancy using medical and obstetric records. The CARPREG I and modified WHO (mWHO) risk classifications were used. Twin pregnancies, miscarriages before gestational week 13, and pregnancy terminations were excluded. Results: Five hundred seventy-one deliveries and 9 late miscarriages were analyzed. The mean parity was 1.74 per woman (range 1–8). Eighty-four (14.6%) maternal cardiac complications were experienced; arrhythmia (5.7%) and heart failure (4.4%) being the most prevalent, and there was 1 maternal death. Heart failure occurred during the first pregnancy in 12 women (3.9%), in the second pregnancy in 8 women (4.3%), and in the third pregnancy in 4 women (7.7%). CARPREG I and mWHO scores were associated with an increased risk of having a cardiac complication, while parity per se was not associated. The OR for having a maternally uneventful second pregnancy if the first pregnancy was without cardiac complications was 5.47 (95% CI 1.76–16.94) after controlling for CARPREG I and mWHO scores. Conclusion: The risk of severe maternal cardiac complications during pregnancy in women with congenital heart disease is low. In this largest analysis to date with a focus on parity in 307 women, the risk classification predicts the maternal outcome more than parity per se. If the first pregnancy is uneventful, the OR is 5.5 for an uneventful second pregnancy if CARPREG I and mWHO scores remain unchanged.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Pregnancy Outcomes in Women With Heart Disease

          Identifying women at high risk is an important aspect of care for women with heart disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center.

            Prediction of adverse maternal and neonatal events in women with heart disease is not well established. We aimed to assess cardiac, obstetrical and neonatal complications in pregnant women with heart disease referred to our tertiary care center and validate a previously proposed risk index.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tobacco Use During Pregnancy.

              Smoking during pregnancy is the most common preventable cause of infant morbidity and mortality. Cessation by the third trimester has consistently been associated with improved birth outcomes; however, the majority of women who obtain cessation during pregnancy, relapse in the first year postpartum. The majority of women who smoke during pregnancy developed their addiction to tobacco in early life, thus the need to intervene in the familial transmission of nicotine dependence is clear. This review discusses the epidemiology of tobacco use amongst pregnant women and factors associated with cessation. Specific intervention strategies are discussed and recommendations are provided to clinicians.
                Bookmark

                Author and article information

                Journal
                CRD
                Cardiology
                10.1159/issn.0008-6312
                Cardiology
                S. Karger AG
                0008-6312
                1421-9751
                2020
                August 2020
                13 July 2020
                : 145
                : 8
                : 533-542
                Affiliations
                [_a] aDepartment of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
                [_b] bCenter for Adults with Congenital Heart Disease (ACHD), Department of Medicine/Östra, Sahlgrenska University Hospital, Gothenburg, Sweden
                [_c] cDepartment of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
                [_d] dDepartment of Obstetrics and Gynaecology, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden
                Author notes
                *Eva Furenäs, Department of Medicine, Östra, Sahlgrenska University Hospital, Diagnosv 11, SE–41685 Gothenburg (Sweden), eva.furenas@vgregion.se
                Author information
                https://orcid.org/0000-0003-3644-6998
                Article
                508649 Cardiology 2020;145:533–541
                10.1159/000508649
                7592600
                32659772
                0dbf1142-794c-4f56-b5b8-5935e8d6fa06
                © 2020 The Author(s) Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 22 September 2019
                : 23 April 2020
                Page count
                Figures: 3, Tables: 3, Pages: 9
                Categories
                Congenital Heart Disease: Research Article

                General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
                Outcome,Parity,Pregnancy
                General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology
                Outcome, Parity, Pregnancy

                Comments

                Comment on this article